Raymond James Maintains Liquidia (LQDA) Buy Rating and Raises Price Target to $77
Raymond James analyst Ryan Deschner has maintained a 'Buy' rating on Liquidia Corporation while increasing the price target from $53 to $77.
Stocks · News reference
Kodiak Sciences, AMC Entertainment, Agenus And Other Big Stocks Moving Higher On Monday
U.S. stocks fell Monday, while Kodiak Sciences surged 174% after positive Phase 3 eye disease trial results; several small caps also rallied.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Corporación América Airports Announces Third Quarter 2026 Financial Results Call and Webcast
Corporación América Airports S.A. has scheduled the release of its third quarter 2026 financial results for November 17, 2026, followed by a conference call on November 18, 2026.
BTIG Analyst Raises Liquidia Price Target to $87
BTIG analyst Julian Harrison has maintained a 'Buy' rating on Liquidia Corporation and increased the price target from $70 to $87.
Pacific Biosciences of California, Inc. Announces $100 Million At-the-Market Equity Offering
Pacific Biosciences of California, Inc. has entered into a sales agreement with Allen & Company to sell up to $100 million of its common stock through an at-the-market offering.
Needham Maintains Buy Rating and Raises Price Target for Liquidia
Needham has reaffirmed its 'Buy' rating on Liquidia Corporation and increased its price target for the company's stock to $66.
8-K filing — PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB)
Filed: 2026-11-10 AccNo: 0001104659-26-125166 Size: 603 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits